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Figure 1. RSV trend in pediatric HSCT recipients
Abstracts / Biol Blood Marrow Transplant 21 (2015) S206eS239 S227therapy. Both patients with drug resistant virus developed
CMV disease. In contrast, 3 patients (8.8%) were not
screened or negative for resistant virus and had CMV
disease.
Discussion: Drug resistant CMV in pediatric HSCT re-
cipients is rare and associated morbidity is poorlyFigure 2. Demographics, risk factors ancharacterized. Anti-viral exposure may not be associated
with drug resistant virus in this population. Our data im-
plies a potential risk for community acquired ganciclovir
resistant virus. Both patients with drug resistant virus had
clinical disease suggesting patients with drug resistant
virus are at greater risk of developing CMV disease. A
prospective evaluation of gene mutation status at reac-
tivation, after anti-viral therapy, with elevated viral load
and with prolonged viremia is needed to better charac-
terize drug resistant CMV.306
Trend, Risk Factors and Outcome of Respiratory Syncytial
Viral Infection in Pediatric Hematopoietic Stem Cell
Transplant Recipients: A Multi-Institutional Review
Ram Kalpatthi 1, Matt Hall 2, Nazia Tabassum3, Nancy Shreve 4,
Leigh Casey 3, Jignesh Dalal 5. 1 Hematology Oncology and BMT,
Children’s Mercy Hospital, Kansas City, MO; 2 Children’s Hospital
Association, Overland Park, KS; 3 Children’s Mercy Hospital,
Kansas City, MO; 4Hematology/Oncology, Children’s Mercy
Hospital, Kansas City, MO; 5 Section of Stem Cell Transplant,
Children’s Mercy Hospital, Kansas City, MOd outcome of patients with RSV
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Abstracts / Biol Blood Marrow Transplant 21 (2015) S206eS239S228Introduction: Respiratory syncytial virus (RSV) is a common
cause of serious respiratory infections in hematopoietic
stem-cell transplant (HSCT) recipients. Infection of the upper
airways may progress to lower airway leading to mortality
especially in young children. In spite of being a common
infection, there is paucity of data about its prevalence, efﬁ-
cacy of prevention, risk factors for infection and mortality in
pediatric HSCT recipients.Methods: We used the Pediatric Health Information System
(PHIS), an electronic database of children’s hospitals in the
US. Patients under the age of 21 who underwent HSCT at one
of the 42 PHIS hospitals from 2000-2013 were analyzed. We
abstracted data on demographics, hospitalizations, medica-
tions, RSV and other HSCT related complications.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S206eS239 S229Results: From 2000 to 2013, a total of 13795 unique pe-
diatric patients who received HSCT were identiﬁed. Among
these 1023 (7.4%) children were identiﬁed to have the
diagnosis of RSV. Out of 1023 children with RSV, 19%
required ICU care and 14% required mechanical ventilation.
Overall, the trend of RSV diagnosis was stable in our cohort
(Figure 1). The demographic characteristics, risk factors
and outcome of these children with and without RSV are
shown in Figure 2. RSV was signiﬁcantly associated with
allogeneic HSCT (p¼<0.001), CMV (p¼<0.001), fungal
infection (p¼<0.001) and GVHD (p¼<0.001). Prophylactic
Pavilizumab was associated with lower risk of RSV only
in patients <1 year of age (24% vs. 76%, p¼<0.0001). The
mortality was signiﬁcantly higher in patients with RSV
compared to those without (18.6% vs. 11.4%, p <0.001).
However, there was no difference in median time (days)
to mortality following HSCT in patients with or without
RSV (1427 [615, 2769] vs. 1554 [613, 3038], p¼0.1).
Multivariate logistic regression analysis of age, gender,
HSCT type, CMV, GVHD, concurrent viral and bacterial
respiratory infections, Pavilizumab, IVIG, Respigam and
Ribavirin showed only older age i.e. 10 years at the time
of HSCT [HR 2.17 (1.35, 3.48), p¼<0.001], GVHD [HR 1.36
(1.01, 1.84), p¼0.041] were associated with increased
mortality whereas the use of IGIV [HR 0.74 (0.54, 0.99),
p¼0.049] was protective in patients with RSV (Figure 3).
Conclusions: Ours is the largest cohort of RSV following
HSCT in children with the prevalence of 7.4%. The mortality
in our pediatric cohort is 18.6% which is similar to previ-
ously publishes case series. Older patients, GVHD were
associated with increased mortality whereas Pavilizumab
not associated with improved survival in our study. Further
studies are needed to explore effective RSV prophylactic
strategies and the use of novel therapies to optimize the
outcome.307
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Background: Sickle cell disease (SCD) is a state of chronic
inﬂammation and hypercoagulability. Previous studies have
demonstrated that patients with SCD experience higher rates
of perioperative complications when compared to normal
patients. Although SCD is considered a hypercoagulable
disease, intra-operative bleeding has been reported as a
signiﬁcant complication. Patients with SCD who are
admitted for surgical procedures often are found to have
prolonged prothrombin times (PT), which may contribute to
the risk of bleeding. Matched-related donor (MRD) bone
marrow transplant (BMT) offers a cure for patients with SCD.
Matched-related donors often have sickle cell trait (SCT). We
anecdotally observed multiple MRD with SCT and mild pro-
longation of the PT. This prompted a systematic examination
of a series of MRD for coagulation values, SCT status, and the
incidence of bleeding complications with the bone marrow
harvest.
Methods: Retrospective chart review of MRD BMT donors for
sickle cell disease between 1/2005-10/2014 to compare PT,
partial prothrombin times (PTT), international normalized
ratio (INR), and the incidence of bleeding complications indonors with and without SCT. Mann-Whitney and Fisher’s
Exact test were used for statistical analyses.
Results: Twenty-ﬁve donors were included in the analysis.
Median age of donors was 9.8 years (range 2.6-25.3). None of
the donors had bleeding complications with the bone
marrow harvest. Sixteen of the twenty-ﬁve (64%) donors had
SCT. Of the 16 patients with SCT, 5(31%) had a prolonged PT,
whereas only 1/9 (11%) of patients without SCT had a pro-
longed PT. Although the trend was suggestive, the sample
size was too small to show that the difference was statisti-
cally signiﬁcant (p¼0.36). There was also no signiﬁcant dif-
ference in INR or PTT. The average PT in SCT patients with
prolonged PT was 15.1 seconds (14.2-16.1), and average INR
was 1.23 (1.16-1.33).
Conclusions: Our series suggests that patients with SCT tend
to have prolonged PT when compared to normal controls.
However, despite the prolongation in PT, none of the donors
experienced signiﬁcant perioperative complications,
including bleeding. The cause of this prolongation in PT in
patients with SCT remains uncertain, but may be a result of
low levels of sickling in the kidneys, mild liver dysfunction,
or vitamin K deﬁciency. A planned multi-center study
examining coagulation values and bleeding complications in
donors with and without sickle cell trait should allow
conﬁrmation of the ﬁnding that there is no increased risk of
perioperative bleeding in these donors and that donors with
SCT have a statistically signiﬁcant increase in the incidence of
prolonged PT. That determination would be timely given the
increasing numbers of patients being transplanted for SCD,
many of whose related donors will have the trait.308
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Background: Adoptive immunotherapy using virus-speciﬁc
cytotoxic T-lymphocyte (VSTs) products has been successful
in restoring antiviral immunity after hematopoietic stem cell
transplantation (HSCT), and has been used to treat patients
with primary immunodeﬁciency (PIDD). Theymay also be an
invaluable salvage therapy for refractory viral infections
prior to HSCT. VST can be produced from virus-exposed do-
nors in as little as 10-14 days, and new protocols allow VST
production from virus-naïve donors in 4-5 weeks.
Objective: To evaluate the clinical efﬁcacy of VSTs for the
prevention and treatment of CMV, EBV, and Adenovirus in
patients with PIDD both before and after HSCT.
Design/Methods: VSTs were cultured from HSCT donors
using peptide pulsed antigen presenting cells and cytokines.
VSTs were tested for speciﬁcity and non-alloreactivity via
IFN-g ELISpot and cytotoxicity assays. Patients were followed
for 45 days following infusion for toxicity monitoring and for
>6 months for antiviral response.
